MSK

By Dave Muoio 03:57 pm May 19, 2020
Digital chronic-disease-program company Omada Health is leaping into musculoskeletal care thanks to its acquisition of Physera, an app-based platform that includes remote consultations with physical therapists. Although the deal was announced today, Omada said it will "immediately" begin offering the MSK program to its employer, health plan and individual customers. “Integrating a digital...
By Laura Lovett 01:34 pm February 27, 2020
This morning digital physical therapy program Sword Health announced that it scored $9 million in the second phase of its Series A funding round, which brings the round's total to $17 million. Khosla Ventures led with participation from Founders Fund, Green Innovations, Lachy Groom, Vesalius Biocapital and Faber Ventures. This news comes roughly a year after the startup announced the $8 million...
By Dave Muoio 08:00 am February 4, 2020
Hinge Health, the maker of digital programs for chronic musculoskeletal (MSK) health, has closed $90 million in a new round led by Bessemer Venture Partners. Lead Edge Capital also took part in the Series C, as did prior backers Insight Partners, Atomico, 11.2 Capital, Quadrille Capital and Heuristic Capital. Hinge had been courting investors throughout the course of the last quarter, and...
By Dave Muoio 12:01 pm March 13, 2019
Physera — an app-based platform for musculoskeletal (MSK) exercises and remote consultations with physical therapists — has raised $8 million in a Series A round headed by BlueCross BlueShield Venture Partners. With this, the company has now raised more than $10 million in total, and counts Innovation Endeavors, Lux Capital, Expa, Slow Ventures, iD Ventures, J-Angels, Rock Health’s Halle Tecco...
By Laura Lovett 03:25 pm February 6, 2018
Paige.AI, a health technology company that applies artificial intelligence to pathology for cancer diagnosis and treatment, recently announced it landed $25 million in Series A funding, led by Jim Breyer of Breyer Capital.  “Patients deserve and need an accurate diagnosis as quickly as possible, yet our current methods are time-consuming, expensive and subjective,” Dr. David Klimstra, cofounder...